Borax‐Doped Fe 2 O 3 and CeO 2 Nanoparticles Regulate Dose‐Dependently Inflammation, the Cell Cycle, and Migration in LPS‐Activated THP‐1 Cells

View at publisher Summarise with VIRAT
Authors: Büşra Acar, Nihan Aktaş Pepe, Yağmur Ceylan Ekiz, Mine Sulak, Alaattin Şen, Gurbet Çelik Turgut
Cited by: 0
References: 80

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT This study examined the biological effects of borax‐doped Fe 2 O 3 and CeO 2 nanoparticles (NPs) on lipopolysaccharide (LPS)‐activated THP‐1 cells. The morphology and composition of the nanocomposites were confirmed via scanning electron microscopy (SEM) and energy‐dispersive x‐ray spectroscopy (EDX). Cell viability (resazurin and crystal violet assays), apoptosis/necrosis (annexin V/propidium iodide [PI]), cell cycle (flow cytometry), migration (scratch assay), and inflammatory response (Iba1 immunofluorescence staining, inducible nitric oxide synthase [iNOS] activity, and RT‐PCR) were evaluated. The particle sizes ranged from 21.34 to 33.47 nm (Fe 2 O 3 ‐B‐NPs) and 31.07 to 36.62 nm (CeO 2 ‐B‐NPs). The IC 10 and IC 50 dose ranges were defined for each nanocomposite and applied across different cell lines to evaluate dose‐dependent biological effects. Fe 2 O 3 ‐B‐NPs altered cell cycle progression, increasing the number of S phase cells. Both nanocomposites promoted migration at low doses but inhibited it at high doses. CeO 2 ‐B‐NPs reduced Iba1 levels, whereas Fe 2 O 3 ‐B‐NPs increased inflammatory marker levels at higher concentrations. CeO 2 ‐B‐NPs suppressed TNF‐α and IL‐1β gene expression at the IC 50 dose, while both nanocomposites reduced iNOS activity. These results indicate that the dose‐dependent effects of nanocomposites should be carefully evaluated.

Fields of Study & Subjects

Nanoparticles: synthesis and applications Immunotoxicology and immune responses Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Chemistry & Biodiversity
Volume
23
Issue
3
Pages
e01819–e01819
Publication date
1 March 2026
Language
EN